## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Lin, et al.

Serial No.:

08/182,183

Group Art Unit No.:

1817

Filed:

May 23, 1994

Examiner:

M. Allen

For:

Gliat Cell Line-Derived Neurotrophic Factor

Docket No.:

S-225E

## ATTORNEY'S STATEMENT PURSUANT TO § 1.821(f)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

I hereby state that the paper copy and the computer readable form (CRF) of the "Sequence Listing" submitted herewith for the above-mentioned patent application are the same. Please replace pages 92 through 99d in the specification with the new enclosed pages 92 through 99e.

Respectfully submitted,

Daniel R. Curry

Attorney for Applicants

Registration No.: 32,727 Phone: (805) 447-8102 Date: January 16, 1998

Please send all future correspondence to:

U.S. Patent Operations/DRC M/S 10-1-B AMGEN INC. Amgen Center 1840 DeHavilland Drive Thousand Oaks, California 91320-1789

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patients, Washington, D.C. 20231, on the date appearing below.

January 16, 1998

7. Cigo